<DOC>
	<DOCNO>NCT02307838</DOCNO>
	<brief_summary>This study collect follow-up data approximately 90 % participant randomize receive one dose study drug FTY720D2201 ( D2201 ) . No study drug give require . Participants require assessed one two visit , preferably original study site , option interview via phone see home provide . Information gather also deceased participant . Assessments perform within 8 week period include medical history , Multiple Sclerosis ( MS ) Multiple Sclerosis Disease Modifying Therapy ( MS DMT ) history , Expanded Disability Status Scale ( EDSS ) , Magnetic Resonance Imaging ( MRI ) , Multiple Sclerosis Functional Composite ( MSFC ) .</brief_summary>
	<brief_title>Long-term Follow-up Fingolimod Phase II Study Patients</brief_title>
	<detailed_description>This multicenter follow-up study patient originally enrol Phase 2 D2201 study . Patients receive protocol specify treatment . The original D2201 study site agree participate study require locate patient randomize Study D2201 ask return 10-year assessment , regardless current treatment status . Locating patient may require use search advertising strategy find patient currently lose follow-up , accordance local privacy legislation . Patients currently follow within Study FTY720D2399 ( NCT01201356 ) ask participate Study FTY720D2201E2 patient give consent , enrol concurrently study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Written informed consent must obtain assessment perform . Randomized study FTY720D2201 receive least one dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Sclerosis , MS , RRMS , relapse form multiple sclerosis , fingolimod , FTY720 , Gilenya</keyword>
</DOC>